Eisai's Named Patient Access Programme for Fycompa® (perampanel) Available from 1 January 2014

Eisai's Named Patient Access ProgrammeEisai's Named Patient Access Programme for Fycompa® (perampanel) Available from 1 January 2014 PR Newswire HATFIELD, England, December 11, 2013 Named patient access programme ensures patients receive uninterrupted supply of Fycompa at no cost to the German healthcare system ®Eisai today announces that Fycompa (perampanel) will be ready to be supplied on a named patient basis from the 1 January 2014 onwards. This follows the temporary suspension of the commercial distribution (Aussetzen des Vertriebes) of the antiepileptic drug (AED) in Germany earlier this year. The named patient access programme will be managed by Clinigen Global Access Programs (Clinigen GAP), part of Clinigen Group plc and will ensure that all patients on the programme continue to receive an ®uninterrupted supply of Fycompa at no cost to the German healthcare system. For all further enquiries and further information about the access programme, contact Clinigen GAP: Tel: +49-(0)69-22223413 Fax: 0800 5892457 Email: customer.services@clinigengroup.com (Please note that to ensure successful communication, we recommend to add this email address to your approved list of contacts) Discovered and developed by Eisai in the UK and Japan, perampanel is the first and only approved AED in Europe with a mode of action that selectively targets AMPA receptors, thought to play a central role in seizure [1]generation and spread.